Stock analysts at Cantor Fitzgerald initiated coverage on shares of Johnson & Johnson (NYSE:JNJ) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set an “overweight” rating on the stock.

JNJ has been the topic of several other reports. Raymond James reduced their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a report on Tuesday, August 27th. Credit Suisse Group increased their target price on Johnson & Johnson from $158.00 to $163.00 in a report on Thursday, October 24th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price on the stock in a report on Thursday, October 17th. Finally, Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Friday, October 11th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus price target of $151.64.

Shares of JNJ traded down $0.01 during trading hours on Tuesday, hitting $134.82. 4,332,729 shares of the company were exchanged, compared to its average volume of 7,198,258. The company has a market cap of $355.14 billion, a price-to-earnings ratio of 16.48, a P/E/G ratio of 2.28 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The firm’s fifty day moving average is $131.30 and its 200 day moving average is $133.76.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 EPS. Analysts anticipate that Johnson & Johnson will post 8.66 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in JNJ. Virtus ETF Advisers LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $25,000. Krane Funds Advisors LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $26,000. Financial Advantage Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter valued at about $28,000. Crewe Advisors LLC boosted its stake in shares of Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Finally, Eii Capital Management Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter valued at about $39,000. 72.21% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is a Call Option?

The Fly

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.